Healthcare provider profile · identity verified

Thomas Edward Madaj, MD

Internal Medicine · TULSA, OK · NPI 1356398358

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	439	150
Amlodipine Besylate	Amlodipine Besylate	387	133
Atorvastatin Calcium	Atorvastatin Calcium	245	82
Levothyroxine Sodium	Levothyroxine Sodium	237	72
Losartan Potassium	Losartan Potassium	214	77
Potassium Chloride	Potassium Chloride	181	58
Lisinopril	Lisinopril	175	63
Eliquis	Apixaban	156	32
Metformin Hcl	Metformin Hcl	143	59
Metoprolol Succinate	Metoprolol Succinate	131	49
Ozempic	Semaglutide	125	21
Trazodone Hcl	Trazodone Hcl	118	33
Furosemide	Furosemide	117	41
Escitalopram Oxalate	Escitalopram Oxalate	116	30
Omeprazole	Omeprazole	116	35
Pantoprazole Sodium	Pantoprazole Sodium	114	40
Tamsulosin Hcl	Tamsulosin Hcl	110	39
Alendronate Sodium	Alendronate Sodium	102	27
Bupropion Xl	Bupropion Hcl	100	27
Gabapentin	Gabapentin	100	34
Simvastatin	Simvastatin	98	29
Spironolactone	Spironolactone	97	35
Chlorthalidone	Chlorthalidone	93	35
Hydrochlorothiazide	Hydrochlorothiazide	89	32
Albuterol Sulfate Hfa	Albuterol Sulfate	88	29
Ezetimibe	Ezetimibe	82	27
Diclofenac Sodium	Diclofenac Sodium	77	23
Allopurinol	Allopurinol	72	24
Mirtazapine	Mirtazapine	72	18
Duloxetine Hcl	Duloxetine Hcl	70	21
Fluoxetine Hcl	Fluoxetine Hcl	70	15
Tramadol Hcl	Tramadol Hcl	69	20
Clopidogrel	Clopidogrel Bisulfate	60	23
Pioglitazone Hcl	Pioglitazone Hcl	58	19
Glipizide	Glipizide	57	22
Alprazolam	Alprazolam	56	20
Montelukast Sodium	Montelukast Sodium	56	19
Prednisone	Prednisone	56	43
Carvedilol	Carvedilol	55	20
Jardiance	Empagliflozin	52	18
Mounjaro	Tirzepatide	51	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	49	20
Sertraline Hcl	Sertraline Hcl	43	15
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	42	12
Pravastatin Sodium	Pravastatin Sodium	42	11
Celecoxib	Celecoxib	41	suppressed
Ropinirole Hcl	Ropinirole Hcl	38	suppressed
Irbesartan	Irbesartan	37	suppressed
Fluticasone Propionate	Fluticasone Propionate	36	11
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	35	13
Donepezil Hcl	Donepezil Hcl	35	11
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	35	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	34	suppressed
Clonazepam	Clonazepam	33	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	33	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	32	14
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	32	11
Baclofen	Baclofen	31	suppressed
Buspirone Hcl	Buspirone Hcl	31	suppressed
Januvia	Sitagliptin Phosphate	30	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	29	11
Hydralazine Hcl	Hydralazine Hcl	28	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	28	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	28	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	28	suppressed
Atenolol	Atenolol	26	12
Breo Ellipta	Fluticasone/Vilanterol	26	suppressed
Gemfibrozil	Gemfibrozil	26	suppressed
Meloxicam	Meloxicam	25	12
Memantine Hcl	Memantine Hcl	25	suppressed
Pregabalin	Pregabalin	25	suppressed
Valsartan	Valsartan	25	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	25	suppressed
Citalopram Hbr	Citalopram Hydrobromide	24	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	24	suppressed
Ondansetron Hcl	Ondansetron Hcl	24	suppressed
Tizanidine Hcl	Tizanidine Hcl	24	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	23	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	22	19
Ondansetron Odt	Ondansetron	22	suppressed
Verapamil Er	Verapamil Hcl	22	suppressed
Bupropion Hcl Sr	Bupropion Hcl	20	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	20	suppressed
Estradiol (Twice Weekly)	Estradiol	19	suppressed
Novolog Flexpen	Insulin Aspart	19	suppressed
Sildenafil Citrate	Sildenafil Citrate	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	suppressed
Paroxetine Hcl	Paroxetine Hcl	18	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	17	suppressed
Metformin Hcl Er	Metformin Hcl	16	suppressed
Benazepril Hcl	Benazepril Hcl	15	suppressed
Lorazepam	Lorazepam	15	suppressed
Trintellix	Vortioxetine Hydrobromide	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	suppressed
Entresto	Sacubitril/Valsartan	14	suppressed
Estradiol	Estradiol	14	suppressed
Verapamil Sr	Verapamil Hcl	14	suppressed
Warfarin Sodium	Warfarin Sodium	14	suppressed
Clonidine Hcl	Clonidine Hcl	13	suppressed
Famotidine	Famotidine	13	suppressed
Finasteride	Finasteride	13	suppressed
Klor-Con M20	Potassium Chloride	13	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Farxiga	Dapagliflozin Propanediol	12	suppressed
Gemtesa	Vibegron	12	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	12	suppressed
Ibuprofen	Ibuprofen	12	suppressed
Azithromycin	Azithromycin	11	11
Incruse Ellipta	Umeclidinium Bromide	11	suppressed
Ipratropium Bromide	Ipratropium Bromide	11	suppressed
Lamotrigine	Lamotrigine	11	suppressed
Levetiracetam	Levetiracetam	11	suppressed
Linzess	Linaclotide	11	suppressed
Methocarbamol	Methocarbamol	11	suppressed
Olanzapine	Olanzapine	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed
Sucralfate	Sucralfate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error